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Hepatitis C virus in Zimbabwe
I^T GANGAIDZO, *VM MOYO, *H KHUMALO, *T SAUNGWEME, **ZAR GOMO, ***T ROUAULT, *VR
GORDEUK
background: Hepatitis B is a common cause of chronic liver disease in Zimbabwe but other viral infections 
jtc also important. The prevalence of viral hepatitis C has not been previously described in healthy rural 
Qmbabwean adults.
Objectives: To determine the prevalence of seropositivity to hepatitis C in rural healthy adults in Zimbabwe, 
tnd to determine if there is evidence of active liver disease in subjects who are seropositive.
MtodyDesign: Cross sectional descriptive study.
Petting; Rural communities around different parts of Zimbabwe, as part of a larger study into the prevalence 
pod genetic pattern of iron overload.
fSubjects: An initial 150 rural Zimbabweans over the age of 12 years.
Man Outcome M ea su res:  Presence of the following serological markers: hepatitis B surface antigen; 
antibodies to hepatitis C, B surface and B core antigens; hepatic enzymes and iron status determined on the 
basis of serum ferritin and transferrin saturation.
Results:! 1 (7.7%) of the subjects were positive for antibodies to hepatitis C and they had significant elevations 
in hepatic enzymes and serum iron levels suggesting substantial hepatocellular damage. Twenty (14.1%) of 
the subjects were positive for hepatitis B surface antigen, but they did not have significant elevations in hepatic 
enzymes or indirect measures of iron status.
Conclusion: Seropositivity for hepatitis C is common and is approximately half the prevalence of hepatitis 
Bchronic carrier status. Chronic hepatitis C may be more damaging to the liver than chronic hepatitis B and, 
therefore, may be an important cause of liver disease in rural Zimbabwe.
Introduction
Liverdisease is an important cause of morbidity and mortality 
in Zimbabwe, accounting for more than six per cent of the 
deaths in three medical wards of Harare Central Hospital (IT 
Gangaidzo, 1994, unpublished observations). In western 
countries, HCV infection is the most common cause of 
chronic viral hepatitis and ranks a slight second below chronic 
alcoholism as a cause of cirrhosis, liver failure and hepatoma.1
Infection with hepatitis B (HBV) is a major aetiological 
factor in many liver diseases in southern Africa,23 but the 
contribution of hepatitis C virus (HCV) in causing hepatic 
pathology is unclear.4 In much of sub-Saharan Africa including 
Zimbabwe, the mode of transmission and the seroprevalence 
of antibody to HCV (anti-HCV) are still to be established. 
Most published studies from sub-Saharan Africa give 
prevalence rates of anti-HCV in special groups such as blood 
donors or hospital patients suffering from liver disease.5 In
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the present study, we attempted to provide an initial 
approximation of the prevalence of anti-HCV in otherwise 
healthy Zimbabweans and to identify some consequences of 
seropositivity.
M aterials and M ethods
Selection of Subjects.
The data set for the present study was collected as part of an 
investigation into the prevalence and genetic pattern of iron 
overload among 150 Zimbabweans. Study subjects were 
selected in one of two patterns.
1. Sixty one subjects were predominantly husband and 
wife pairs from the rural Zaka District of Masvingo 
province, about 300 km southeast of Harare, who were 
studied from February to May of 1994. One of the 
spouse pairs was selected on the basis of an index 
subject showing increased hepatocellular iron on a 
diagnostic liver biopsy specimen. These subjects were 
of Shona and of Shangaan origin. The individual 
members of the spouse pairs were not closely related to 
each other because of the tabooof marrying even distant 
relations.
2. Eighty nine subjects were members of five families that 
were selected on the basis of an index subject with 
increased hepatocellular iron identified on diagnostic 
liver biopsy. These families, predominantly of Shona 
origin, were based in Mrewa(25 subjects), Sanyati (18), 
Buhera (17), Honde Valley (16) and Chegutu (13).
All subjects provided informed consent. Demographic 
factors included a history of injections, jaundice, blood 
transfusion and surgery. An estimate was made of lifetime 
traditional beer consumption for each individual as previously 
described.6 
Laboratory Tests.
Peripheral blood samples were analysed for anti-HCV by a 
third generation solid phase enzyme immunoassay (EIA) 
consisting of recombinant antigens encoded by the HCV 
(ABBOTT HCV EIA 3.0®). The presence of anti-HCV was 
confirmed by re-testing using the same procedure. Positive 
sera were also tested by the Abbott HCV EIA Supplemental 
Assay. Hepatitis B antigen (HBsAg) was assayed using a 
commercial EIA kit (AUSAB EIA®). Specimens that were 
non-reactive by the test were considered negative for HBsAg 
and were not tested further. Specimens that had a positive 
reaction were tested again in duplicate using the same 
procedures. If neither of the repeat tests were reactive, the 
specimens were considered negative for HBsAg. If the 
specimen was reactive in either of the repeat tests, the sample 
was regarded as positive for HBsAg. The samples were also 
screened undiluted for anti-HBs antibody (AUSZYME 
MONOCLONAL®),and anti-HB core antibody (CORZYME 
RECOMBINANT®). The serological kits were supplied by 
Abbott Laboratories (Abbott Park, Illinois).
The assessment of the elevation in hepatic enzymes due to 
viral hepatitis is confounded by the contribution of alcohol 
ingestion and by the presence of iron overload. Serum ferritin 
and hepatic enzymes such as aspartate amminotransferase, 
may reflect active hepatocellular damage. Since excess dietary 
iron is derived from traditionally brewed beer we wished to 
assess the degree to which elevated serum ferritin may reflect
increased body iron stores versus viral or alcohol induced 
hepatocellular damage. The ratio of serum ferritin to aspartate 
amminotransferase (ferritin: AST) has been shown tocorrelaie 
well with the hepatic iron concentration7 and to be constant* 
a given patient both in the setting of acute alcohol ingest** 
and after prolonged abstension from alcohol.8
Serum ferritin was determined using an enzyme immuno­
assay and transferrin saturation was obtained by dividingtht 
• serum iron by the total iron binding capacity and multiplyin 
by 100, as previously described.6 Liver function tests we# 
measured on a Cobus Bio auto-analyser using reagents fro* 
Roche Diagnostic Systems, South Africa.
Statistical Analysis.
Index subjects who had a diagnostic liver biopsy and their 
spouses were excluded from the analysis for they had comelo 
light because of clinical liver disease and might bias the 
results toward a higher prevalence of viral hepatitis. Ratesof 
positivity for hepatitis markers were compared according!) 
age category using the Fisher exact test (Table I). Ratesof 
positivity for hepatitis markers according to five family 
groupings were compared using Pearson’s chi square test 
Estim ated lifetim e beer trad itional consumption, 
gammaglutamyl transferase, alanine aminotransferase,sera* 
ferritin and ratio of ferritin to AST had skewed distributions 
and were log-transformed before statistical analyses. 
Continous variables were compared according to viral hepatitis 
status using analysis of variance models.
Age, sex and estimated beer consumption were covariates 
for the analyses of hepatic enzymes and indirect measuresof 
iron status (Tables II and III). The categorical variable ofsa 
was compared according to hepatitis status using Fisher’s 
exact test.
Results
After exclusion of six index subjects and two spouses thedatt 
set consisted of 142 subjects, 72 males and 70 females with 
ages ranging from 12 to 84 years. Eleven subjects (7.7%) 
were positive for anti-HCV (Table 1). For comparison, 20 
subjects (14.1%) were positive for HBsAg, and 107 of 142 
(75.3%) were positive for at least one of the following 
HBsAg, HBsAb and HBcAb. Only one subject was positive 
for both anti-HCV and HBsAg. The prevalence of HCV 
antibody was significantly higher in subjects over40 yearsof 
age while the prevalence of HBsAg was significantly lower 
in this age group.
Table I: Prevalence o f serum markers fo r  hepatitis C and 
hepatitis B according to age; p values indicate comparison
between age categories.
Age
category
(years) n
HCV
antibody
positive
n(% )
HBsAg
positive
n(% )
positive HBsAgt- 
HBsAb, HBctt*
n(%)
<40 64 1 (1.6) 15(23.4) 43(67.2)
>40 78 10(12.8) 5(6 .4) 64 (82.1)
(P) (0.013) (0.007) (0.051)
All 142 11(7.7) 20(14.1) 107(75.3)
*Positive for any one or more of hepatitis B surface antigen, antl-turlm 
antibody and anti-core antibody (indicating previous exposure).
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Theprcvalenceof anii-HCV ranged from 0% to 33% in five 
different family groupings and the difference in proportions 
litre not statistically significantly different (p=0.18). The 
ifrovalenceof HBsAg ranged from 0% to 75% in five family 
(roupingsand the differences in proportions were statistically 
ilignificant (p<0.0001).
Table II shows that hepatic enzymes were significantly 
[fkvated in subjects positive for antibody to hepatitis C. 
Tkansfenin saturations and unsaturated iron binding capacities 
5 twealso significantly elevated in hepatitis C antibody positive 
Objects while serum ferritins and the ratios of ferritin to AST 
m e not. Table III shows that neither hepatic enzymes nor 
■direct measures of iron status were significantly elevated in 
ptients positive for hepatitis B surface antigen.
Table II: Demographic and clinical features according to 
IKIV status. Except for sex, results are given as mean ±SE 
«rgeometric mean and SE range. Values fo r  liver function 
mi iron-related tests have been adjusted for age, sex and 
(Stim tedbeer consumption.
Positive for 
antibody 
t o  H C V
( n = 1 1 )
Negative for 
antibody 
to HCV 
(n=131) P
Age (years) 5 9 + 6 4 6 ± 2 0 0 3
Sex(M:F)
Estimated life tim e  t r a d it io n a l
5 :6 6 7 :6 4 0 .7
beer consum ption (L ) 1 0 5 9  ( 2 8 2 - 3  9 8 1 ) 3 5 9  ( 2 4 4 - 5 0 6 ) 0 .4
T-gtutamyl t ra n s fe ra s e  ( IU ) 6 7  ( 5 3 - 8 5 ) * 2 0  ( 1 9 - 2 1 ) * * < 0 .0 0 0 1
A cp arta le am in o tra ns fe ra se  ( IU ) 5 2  ( 4 5 - 6 0 ) * 2 6  ( 2 5 - 2 7 ) < 0 .0 0 0 1
Alanine a m in o tra n s fe ra s e  ( IU ) 3 9  ( 3 3 - 4 6 ) * 2 0 ( 1 9 - 2 1 ) < 0 .0 0 0 1
Ferritin (pg/m 1) 2 2 6 ( 1 6 5 - 3 1 0 ) 1 4 0  ( 1 2 8 - 1 5 4 ) 0 .1 5
F ta n /A S T  ra tio  (p g /m l) 4 .1  ( 2 .9 - 5 .6 ) 4 .2  ( 3 .9 - 4 .7 ) 0 .9
rtensferrin s a tu ra tio n  (% ) 
Unsatuiated iron  b in d in g
5 8 ± 5 3 6 + 2 0 ,0 0 0 5
capacity (pg /dL) 1 2 4 + 2 0 1 8 0 + 6 0 0 0 7
tetO, "n-129.
fable III: Demographic and clinical features according to 
msence or absence o f HBsAg. Except for sex, results are 
pen as mean ±SE or median and SE range. Values for  
iver function and iron related tests have been adjusted for  
ige, sex and estimated beer consumption.
HBsAg positive HBsAg negative 
(n=20) (n=122) p
(e  (years) 3 8 + 4 4 9 + 2 0 .0 1 9
let(M:F)
s ta te d  life t im e  t r a d it io n a l
1 4 :6 5 8 :6 4 0 .0 9 0
eerconsum ption  (L ) 3 2 ( 1 2 - 8 2 ) 5 8 9  ( 4 0 0 - 8 6 7 ) 0 .0 0 5
'■glutamyl t r a n s fe ra s e  ( IU ) 21 ( 1 8 - 2 6 ) 2 2  ( 2 0 - 2 3 ) * 0 .9
s p a rta te a m in o tra n s fe ra s e  ( IU )  3 3 ( 2 9 - 3 6 ) 2 7  ( 2 6 - 2 8 ) * * 0 ,1 1
J a n in e a m in o tra n s fe ra s e  ( IU ) 2 6  ( 2 3 - 2 9 ) 2 0 ( 1 9 - 2 1 ) * * 0 .0 6 1
t a n  (pg /m l) 1 8 4  ( 1 4 5 - 2 3 4 ) 1 4 0  ( 1 2 8 - 1 5 4 ) 0 .3
ta n /A S T  ra t io  (p g /m l) 5 .0  ( 3 . 9 - 6 . 3 ) 4 .1  ( 3 7 - 4 . 5 ) 0 .5
ransferrin s a tu ra t io n  (% )  
^saturated iro n  b in d in g
4 4 + 4 3 9 + 2 0 .2
ipacity (pg /dL ) 1 5 4 + 1 5 1 8 0 + 6 0 .1 3
fcttf, "n=121.
Discussion
This study is limited in that the data set was not a representative 
sample of the Zimbabwe population. Rather, approximately 
40% of the serum samples came from a rural community near 
Masvingo, and the remaining samples were five family 
pedigrees from rural central and western Zimbabwe. None of 
the study subjects were from the Matabeleland province 
which makes up 20% of the whole Zimbabwean population. 
Thus we are unable to provide a precise estimate of the 
prevalence of antibodies to hepatitis C in this population. 
Nonetheless, the finding of a prevalence of almost 8% in this 
data set raises the possibility that hepatitis C infection is very 
common in the rural Zimbabwe population. Furthermore, the 
fact that the prevalence of hepatitis B surface antigen in the 
present study of 14% is similar to the large population survey 
of Tswana el aP lends credence to the possibility that the true 
prevalence of hepatitis C is on the order of magnitude of what 
we found in this study.
The prevalence of anti-HCV in apparently healthy 
individuals varies widely within Africa and estimates range 
between eight and 30% of study subjects.10 However, most of 
these reports are in people presenting for blood donation and 
may not be representative of the respective populations. In 
this study we attempted to estimate the prevalence of anti- 
HCV antibodies in healthy subjects in whom the selection 
was random in relation to identifiable risk factors for HCV 
infection.
Hepatitis C positive patients in the present study had 
evidence of substantial hepatocellular damage. As shown in 
Table II, hepatic enzymes, transferrin saturations and 
unsaturated iron binding capacities were all elevated in 
hepatitis C positive patients, while serum ferritins and the 
ratios of ferritin to AST were not elevated. This picture is 
much more consistent with damage to hepatocytes than with 
iron loading. Interestingly, none of the hepatic enzymes or 
serological iron tests were significan tly elevated in the hepatitis 
B surface antigen positive subjects. Thus, our present findings 
suggest that chronic hepatitis C infection more consistently 
causes hepatocellular dysfunction than chronic hepatitis B 
infection.
Furthermore, these findings indicate that hepatitis C may 
be a major cause of chronic liver disease in Zimbabwe, and 
are in keeping with other studies around the world showing 
thatchronichcpatitisC infection is associated with a substantial 
risk of hepatic injury or hepatic failure necessitating liver 
transplant."
Several strategies have been introduced in various countries 
in sub-Saharan Africa to reduce the prevalence of chronic 
liver disease through vaccination and educational 
programmes.2 The impact of hepatitis B vaccination in 
childhood may be limited by the proportion of chronic liver 
disease cases that is due to other viral infections such as 
hepatitis C since liver disease from infections other than HB V 
remain untreated. Determination of the prevalenceof hepatitis 
C virus may provide essential information in deciding on 
public health strategies and in assessing cost effective 
interventions.
The mode of transmission of HCV infection differs between 
populations. In the West most hepatitis C occurs among
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young adults with high risk behaviour or lifestyles.12 The 
most efficient method of transmission of HCV is through 
large or repeated percutaneous inoculations with infected 
blood. Transmission also seems to occur through occupational 
exposure, sexual actitivy, household contact and perinatal 
exposure. The risk of transmission is then most dependent on 
the titer of virus as well as the mode of transmission.12 The 
modes of transmission in Africa are not identified.
In this study we attempted to identify factors that are 
associated with HCV infection. The prevalences were similar 
in both sexes and among five family groupings. If close 
contact in childhood is an important mode of transmission, as 
occurs in hepatitis B infection13, then one would expect 
clustering of cases within family pedigrees.
Clustering of HBV infection within close relations was 
found in the present study. That such clustering of HCV cases 
is not seen in the five pedigrees that we studied raises the 
possibility that some other mode of transmission may be 
responsible in rural Zimbabweans. We also found increasing 
prevalence of HCV with age, and this finding is in keeping 
with previous reports from Cameroon.10 This finding may 
help in developing a hypothesis for the mode of transmission.
In case control studies, the proportion of patients with 
hepatocellular carcinoma who have circulating antibody to 
hepatitis C virus shows a pronounced geographical variation. 
In Japan, Spain and Italy HCV antibody is present in 47 to 
83% of hepatoma patients, with relative risks of 52 (95% 
confidence intervals 24 to 114).14
In regions, such as Zimbabwe, where hepatitis B virus 
infection is endemic and is the major risk factor for 
hepatocellular carcinoma, antibodies to hepatitis C are present 
in the serum of a smaller proportion (6 to 39%) of patients, 
with relative risks of six (95% Cl of 0.5 to 69).14 HCV 
infection is likely to be an important public health issue in 
sub-Saharan Africa. Further work is required into the modes 
of transmission of HCV and into possible methods of 
controlling infection. Our preliminary study points to the 
need for a larger epidemiologic survey designed to define the 
prevalence, consequences and risk factor for chronic hepatitis 
C infection in the Zimbabwean population.
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